Nanotechnology: Advancing the translational respiratory research

Abstract

Considering the various limitations associated with the conventional dosage forms, nanotechnology is gaining increased attention in drug delivery particularly in respiratory medicine and research because of its advantages like targeting effects, improved pharmacotherapy, and patient compliance. This paper provides a quick snapshot about the recent trends and applications of nanotechnology to various translational and formulation scientists working on various respiratory diseases, which can help paving a new path in developing effective drug delivery system.

Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

“…miRNA is a single strand RNA that consists of 21-25 nucleotides and are produced from primary miRNA via the action of two RNase-III type proteins-Drosha (in nucleus) and Dicer (in cytoplasm) [10,11]. These hinder the translation process through accumulation of mRNA in processing bodies (P-bodies).…”

Chronic respiratory diseases: An introduction and need for novel drug delivery approaches

“…Consequently the currently available treatments reflect the same, as these only target the major symptoms of the disease without offering any long-term relief, both in terms of prevention and cure. Moreover the drugs that are available lack in terms of targeting the biological entities fully, thus requiring more effective drug delivery approaches to alleviate symptoms of CRDs [17] , [18] . We will discuss these key issues in the present chapter.…”

The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

“…Despite the huge burden of major respiratory disease, there is a lack of effective treatments that could limit the disease onset and/or disease progression (Dua, Chellappan, et al, ; Dua, Gupta, Chellappan, Shukla, & Hansbro, ; Dua, Rapalli, et al, ; Dua, Shukla, de Jesus Andreoli Pinto, & Hansbro, ; Rapalli et al, ). Thus, extensive research into potentially novel therapeutics is urgently required.…”